Related Experiment Video
Updated: Jun 8, 2025
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Dapagliflozin's Role in Heart Failure: An Overview of Clinical Trial Evidence
Rizwan H Khan1, Hasham Qureshi2, Zubair Ahmed3
1Internal Medicine, Northern Ireland Medical and Dental Training Agency, Belfast, GBR.
Insights
Sodium-glucose co-transporter-2 (SGLT2) inhibitors like dapagliflozin show promise in treating heart failure (HF). This review confirms dapagliflozin reduces cardiovascular events and mortality in HF patients, establishing its role in management.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure (HF) is a growing global health concern requiring innovative treatments.
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors represent a potential therapeutic class for HF management.
- Dapagliflozin, an SGLT2 inhibitor, is being investigated for its efficacy in HF patients, especially those with reduced ejection fraction (HFrEF).
Purpose of the Study:
- To systematically review and evaluate the safety and effectiveness of dapagliflozin in patients with heart failure.
- To synthesize findings from clinical studies on dapagliflozin's impact on cardiovascular outcomes in HF.
- To explore the mechanistic pathways through which dapagliflozin exerts cardioprotective effects.
Main Methods:
- Systematic review of clinical studies.
- Analysis of safety and efficacy data for dapagliflozin in HF patients.
- Evaluation of cardiovascular event rates and mortality data.
Main Results:
- Dapagliflozin demonstrated consistent improvements in reducing adverse cardiovascular events in HF patients.
- Cardiovascular death rates were reduced across various HF phenotypes with dapagliflozin treatment.
- Mechanistic insights reveal diuretic, hemodynamic, metabolic, and anti-fibrotic effects contributing to cardioprotection.
Conclusions:
- Dapagliflozin plays a significant role in heart failure management, emerging as a key therapeutic option.
- The drug's multifaceted mechanisms support its cardioprotective actions.
- Further research is needed to define long-term outcomes and clinical integration of dapagliflozin in routine HF care.
Abstract:
Heart failure (HF) has become a global health threat, necessitating the development of novel treatment options to address this crisis. Sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as dapagliflozin, may offer significant advantages in the treatment of HF, particularly in patients with reduced ejection fraction (HFrEF). This systematic review combines the findings from clinical studies to evaluate the safety and effectiveness of dapagliflozin in HF patients. The study results demonstrate dapagliflozin's consistent improvements in reducing adverse cardiovascular events, including cardiovascular death rates across different HF phenotypes. Mechanistically, dapagliflozin exerts diuretic and hemodynamic effects, along with its actions on myocardial metabolism, ion transporters, fibrosis, adipokines, and vascular function, which collectively contribute to its cardioprotective effects. This overview emphasizes dapagliflozin's key role in HF management, positioning it as one of the central pillars of the HF treatment regimen. Further studies are essential to fully understand dapagliflozin's long-term effectiveness, safety, and integration into routine clinical practice, ultimately improving patient outcomes in HF.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:23Dipeptidyl Peptidase 4 Inhibitors
01:26Heart Failure Drugs: Inotropic Agents
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones